Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 301-317

  Arkin, Michelle M R ^a   Wells, James A ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIFLUOROPHENYL) 6 [2 [4 (1H IMIDAZOL 1 YLMETHYL)PHENOXY]ETHOXY] 2 PHENYLPYRIDINE; ANTIMYCIN A1; B7 ANTIGEN; BBS 2; CD28 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYCLOSPORIN; CYSTEINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN IIIA; GUANIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN P75; RO 0282750; RO 264550; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

BINDING SITE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; IC 50; MOLECULE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 3142781225     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1343     Document Type: Review

References (177)

1. Stockwin, L. & Holmes, S. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther. 3, 1133-1152 (2003).
2. Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
3. Monoclonal Antibodies Report 2003: Meeting Clinical and Financial Expectations (Visiongain, 2003).
4. Berg, T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem. Int. Ed. Engl. 42, 2462-2481 (2003).
5. Cochran, A. G. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol. 5, 654-659. (2001).
6. Gadek, T. R. & Nicholas, J. B. Small molecule antagonists of proteins. Biochem. Pharmacol. 65, 1-8 (2003).
7. Ockey, D. A. & Gadek, T. R. Inhibitors of protein-protein interactions. Expert Opin. Ther. Pat. 12, 393-400 (2002).
8. Sharma, S. K., Ramsey, T. M. & Bair, K. W. Protein-protein interactions: lessons learned. Curr. Med. Chem. Anti-Canc. Agents 2, 311-330 (2002).
9. Toogood, P. L. Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem. 45, 1-16 (2002).
10. Sulyok, G. A. et al. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective αvβ3 integrin antagonists. J. Med. Chem. 44, 1938-1950 (2001).
11. Goodman, S. L., Holzemann, G., Sulyok, G. A. & Kessler, H. Nanomolar small molecule inhibitors for αv(β)6, α v(β)5, and αv(β)3 integrins. J. Med. Chem. 45, 1045-1051 (2002).
12. Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165-169 (2001),
13. Hoekstra, W. J. & Poulter, B. L. Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Curr. Med. Chem. 5, 195-204 (1998).
14. Mousa, S. A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 6, 534-541 (2002).
15. Scarborough, R. M. & Gretler, D. D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J. Med. Chem. 43, 3453-3473 (2000).
16. Eldred, C. D. & Judkins, B. D. Fibrinogen receptor antagonists: design and clinical applications. Prog. Med. Chem. 36, 29-90 (1999).
17. Ojima, I., Chakravarty, S. & Dong, Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg. Med. Chem. 3, 337-360 (1995).
18. Gadek, T. R. & McDowell, R. S. Discovery of small molecule leads in a biotechnology datastream. Drug Discov. Today 8, 545-550 (2003).
19. Jackson, D. Y. α4 integrin antagonists. Curr. Pharm. Des. 8, 1229-1253 (2002).
20. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti-Canc. Agents 2, 1-17 (2002).
21. Schreiber, S. L. & Crabtree, G. R. The mechanism of action of cyclosporin A and FK506. Immunol Today 13, 136-142 (1992).
22. Lo Conte, L., Chothia, C. & Janin, J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285, 2177-2198 (1999).
23. Bogan, A. A. & Thorn, K. S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1-9 (1998).
24. Clackson, T. & Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. Science 267, 381-386 (1995).
25. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 12, 14-20 (2002).
26. Ma, B., Elkayam, T., Wolfson, H. & Nussinov, R. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc. Natl Acad. Sci. USA 100, 5772-5777 (2003).
27. Sundberg, E. J. & Mariuzza, R. A. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Structure Fold. Des. 8, R137-R142 (2000).
28. DeLano, W. L., Ultsch, M. H., de Vos, A. M. & Wells, J. A. Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283 (2000).
29. Teague, S. J. Implications of protein flexibility for drug discovery. Nature Rev. Drug Discov. 2, 527-541 (2003).
30. Luque, I. & Freire, E. Structural stability of binding sites: consequences for binding affinity and allosteric effects. Proteins S4, 63-71 (2000).
31. Ma, B., Shatsky, M., Wolfson, H. J. & Nussinov, R. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci. 11, 184-197 (2002).
32. Sidhu, S. S., Fairbrother, W. J. & Deshayes, K. Exploring protein-protein interactions with phage display. Chembiochem. 4, 14-25 (2003).
33. Pillutla, R. C. et al. Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J. Biol. Chem. 277, 22590-22594 (2002).
34. Fairbrother, W. J. et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37, 17754-17764 (1998).
35. Lowman, H. B. Bacteriophage display and discovery of peptide leads for drug development. Annu. Rev. Biophys. Biomol. Struct. 26, 401-424 (1997).
36. Schaffer, M. L., Deshayes, K., Nakamura, G., Sidhu, S. & Skelton, N. J. Complex with a phage display-derived peptide provides insight into the function of insulin-like growth factor I. Biochemistry 42, 9324-9334 (2003).
37. Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A. & Lowman, H. B. Stable 'zeta' peptides that act as potent antagonists of the high-affinity IgE receptor. Proc. Natl Acad. Sci. USA 99, 1303-1308 (2002).
38. Wrighton, N. C. et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273, 458-464 (1996).
39. Cwirla, S. E. et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276, 1696-1699 (1997).
40. Scott, J. K. et al. Evidence that a protein-protein interaction 'hot spot' on heterotrimeric G protein βγ subunits is used for recognition of a subclass of effectors. EMBO J. 20, 767-776 (2001).
41. McGovern, S. L., Helfand, B. T., Feng, B. & Shoichet, B. K. A specific mechanism of nonspecific, inhibition. J. Med. Chem. 46, 4265-4272 (2003).
42. Seidler, J., McGovern, S. L., Doman, T. N. & Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477-4786 (2003).
43. McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712-1722 (2002).
44. Carter, P. H. et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl Acad. Sci. USA 98, 11879-11884 (2001).
45. Wiekowski, M. et al. Characterization of potential antagonists of human interleukin 5 demonstrates their cross-reactivity with receptors for interleukin 3 and granulocyte-macrophage colony-stimulailing factor. Eur. J. Biochem. 246, 625-632 (1997).
46. Way, J. C. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. Curr. Opin. Chem. Biol. 4, 40-46 (2000).
47. Woska, J. R. Jr, Morelock, M. M., Jeanfavre, D. D. & Bormann, B. J. Characterization of molecular interactions between intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. J. Immunol. 156, 4680-4685 (1996).
48. Boehm, H. J. et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 43, 2664-2664 (2000).
49. Nelson, B. H. & Willerford, D. M. Biology of the interleukin-2 receptor. Adv. Immunol. 70, 1-81 (1998).
50. Berard, J. L., Velez, R. L., Freeman, R. B. & Tsunoda, S. M. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 19, 1127-1137 (1999).
51. Waldmann, T. A. & O'Shea, J. The use of antibodies against the IL-2 receptor in transplantation. Curr. Opin. Immunol. 10, 507-512 (1998).
52. Zurawski, S. M. et al. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 12, 5113-5119 (1993).
53. Sauve, K. et al. Localization in human interleukin 2 of the binding site to the α chain (p55) of the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 88, 4636-4640 (1991).
54. Emerson, S. D. et al. NMR characterization of interleukin-2 in complexes with the IL-2Rα receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Rα interaction. Protein Sci. 12, 811-822 (2003).
55. Tilley, J. W. et al. Identification of a small molecule inhibitor of the IL-2/IL-2Rα receptor interaction which binds to IL-2. J. Am. Chem. Soc. 119, 7589-7590 (1997).
56. Arkin, M. R. et al. Binding of small molecules to an adaptive protein:protein interface. Proc. Natl Acad. Sci. USA 100, 1603-1608 (2003).
57. Braisted, A. C. et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125, 3714-3715 (2003).
58. Hyde, J., Braisted, A. C., Randal, M. & Arkin, M. R. Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2. Biochemistry 42, 6475-6483 (2003).
59. Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press).
60. McKay, D. B. Unraveling the structure of interleukin-2: reply. Science 257, 412-413 (1992).
61. Mott, H. R. et al. The solution structure of the F42A mutant of human interleukin 2. J. Mol. Biol. 247, 979-994 (1995).
62. Thanos, C., Randal, M. & Wells, J. A. Potent small-molecule binding to a dynamic hot spot on IL-2. J. Am. Chem. Soc. 125, 15280-16281 (2003).
63. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. & Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609 (1992).
64. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
65. van der Merwe, P. A. & Davis, S. J. Molecular interactions mediating T cell antigen recognition. Annu. Rev Immunol. 21, 659-684 (2003).
66. Collins, A. V. et al. The interaction properties of costimulatory molecules revisited. Immunity 17, 201-210 (2002).
67. Egen, J. G., Kuhns, M. S. & Alison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3, 611-618 (2002).
68. Darlington, P. J. et al. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195, 1337-1347 (2002).
69. Stamper, C. C. et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410, 608-611 (2001).
70. Ikemizu, S. et al. Structure and dimerization of a soluble form of B7-1. Immunity 12, 51-60 (2000).
71. Erbe, D. V., Wang, S., Xing, Y. & Tobin, J. F. Small molecule ligands define a binding site on the immune regulatory protein B7. 1. J. Biol. Chem. 277, 7363-7368 (2002).
72. Green, N. J. et al. Structure-activity studies of a series of dipyrazolo[3,4-b:3′,4′-d]pyridin-3-ones binding to the immune regulatory protein B7. 1. Bioorg. Med. Chem. 11, 2991-3013 (2003).
73. Wang, S. et al. Antibodies to B7. 1 define the GFCC'C' face of the N-terminal domain as critical for co-stimulatory interactions. Immunol. Lett. 83, 77-83 (2002).
74. Huang, Z. The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Chem. Biol. 9, 1059-1072 (2002).
75. Burlacu, A. Regulation of apoptosis by Bcl-2 family proteins. J. Cell. Mol. Med. 7, 249-257 (2003).
76. Gross, A., McDonnell, J. M. & Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899-1911 (1999).
77. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647-656 (2002).
78. Huang, D. C. & Strasser, A. BH3-only proteins - essential initiators of apoptotic cell death. Cell 103, 839-842 (2000).
79. L-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997).
80. Kim, K. M. et al. Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry 40, 4911-4922 (2001).
81. Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124-7129 (2000).
82. L. Nature Cell Biol. 3, 173-182 (2001).
83. Tzung, S. P. et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3, 183-191 (2001).
84. Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313-4324 (2001).
85. Lugovskoy, A. A. et al. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J. Am. Chem. Soc. 124, 1234-1240 (2002).
86. L antagonist based on α-helix mimicry. J. Am. Chem. Soc. 124, 11838-11839 (2002 ).
87. Jahnke, W. et al. Second-site NMR screening and linker design. Curr. Top. Med. Chem. 3, 69-80 (2003).
88. Jahnke, W. et al. Second-site NMR screening with a spin-labeled first ligand. J. Am. Chem. Soc. 122, 7394-7395 (2000).
89. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
90. Zhao, J. et al. The initial evaluation of non-peptidic, small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69-77 (2002).
91. Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336-344 (2001).
92. Duncan, S. J. et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123, 554-560 (2001).
93. Yip, C. C. & Ottensmeyer, P. Three-dimensional structural interactions of insulin and its receptor. J. Biol. Chem. 278, 27329-27332 (2003).
94. Shimaoka, M. & Springer, T. A. Therapeutic antagonists and conformational regulation of integrin function. Nature Rev. Drug Discov. 2, 703-716 (2003).
95. Wiesmann, C. & de Vos, A. M. Nerve growth factor: structure and function. Cell. Mol. Life Sci. 58, 748-759 (2001).
96. Alderton, W. K., Cooper, C. E. & Knowles, R. G. Nitric oxide syntheses: structure, function and inhibition. Biochem J. 357, 593-615 (2001).
97. Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 28, 311-339 (2000).
98. Yusuf-Makagiansar, H., Anderson, M. E., Yakovleva, T. V., Murray, J. S. & Siahaan, T. J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22, 146-167 (2002).
99. Shimaoka, M. et al. Structures of the α L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112, 99-111 (2003).
100. Randi, A. M. & Hogg, N. I domain of β 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J. Biol. Chem. 269, 12395-12398 (1994).
101. Liu, G. Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin. Ther. Patents 11, 1383-1393 (2001).
102. Sanfilippo, P. J. et al. Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion. J. Med. Chem. 38, 1057-1059 (1995).
103. Hogg, N., Laschinger, M., Giles, K. & McDowell, A. T-cell integrins: more than just sticking points. J. Cell Sci. 116, 4695-4705 (2003).
104. Carman, C. V. & Springer, T. A. Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr. Opin. Cell Biol. 15, 547-556 (2003).
105. Huth, J. R. et al. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc. Natl Acad. Sci. USA 97, 5231-6236 (2000).
106. Lulpher, M. L. Jr et al. Cellular activation of leukocyte function-associated antigen-1 and its affinity are regulated at the I domain allosteric site. J. Immunol. 167, 1431-1439 (2001).
107. Lu, C., Shimaoka, M., Zang, Q., Takagi, J. & Springer, T. A. Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl Acad. Sci. USA 98, 2393-2398 (2001).
108. Kallen, J. et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292, 1-9 (1999).
109. Last-Barney, K. et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein-protein interaction. J. Am. Chem. Soc. 123, 5643-5650 (2001).
110. Liu, G. et al. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 44, 1202-1210 (2001).
111. Gadek, T. R. et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 295, 1086-1089 (2002).
112. Shimaoka, M., Salas, A., Yang, W., Weitz-Schmidt, G. & Springer, T. A. Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19, 391-402 (2003).
113. Welzenbach, K., Hommel, U. & Weitz-Schmidt, G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J. Biol. Chem. 277, 10590-10598 (2002).
114. Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).
115. Wattanasin, S. et al. 1,4-Diazepane-2-ones as novel inhibitors of LFA-1. Bioorg. Med. Chem. Lett 13, 499-502 (2003).
116. Kelly, T. A. et al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J. Immunol. 163, 5173-5177 (1999).
117. Liu, G. et al. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J. Med. Chem. 43, 4025-4040 (2000).
118. Pei, Z. et al. Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides. J. Med. Chem. 44, 2913-2920 (2001).
119. Winn, M. et al. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure-activity relationship of substituents on the benzene ring of the cinnamide. J. Med. Chem. 44, 4393-4403 (2001).
120. Link, J. T. et al. Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists. Bioorg. Med. Chem. Lett. 11, 973-976 (2001).
121. Legge, G. B. et al. NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. J. Mol. Biol. 295, 1251-1264 (2000).
122. Qu, A. & Leahy, D. J. Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, α L β 2) integrin. Proc. Natl Acad. Sci. USA 92, 10277-10281 (1995).
123. Qu, A. & Leahy, D. J. The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin. Structure 4, 931-942 (1996).
124. Davidson, W. et al. Characterization of the allosteric inhibition of a protein-protein interaction by mass spectrometry. J. Am. Soc. Mass. Spectrom. 14, 8-13 (2003).
125. Woska, J. R. Jr et al. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J. Leukoc. Biol. 70, 329-334 (2001).
126. Woska, J. R. Jr et al. Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay. J. Immunol. Methods 277, 101-115 (2003).
127. Burdick, D. J. et al. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. Bioorg. Med. Chem. Lett 13, 1015-1018 (2003).
128. Thibault, G. Sodium dodecyl sulfate-stable complexes of echistatin and RGD-dependent integrins: a novel approach to study integrins. Mol. Pharmacol. 58, 1137-1145 (2000).
129. Ignarro, L. J., Cirino, G., Casini, A. & Napoli, C. Nitric oxide as a signaling molecule in the vascular system: an overview. J. Cardiovasc. Pharmacol. 34, 879-886 (1999).
130. Gyurko, R., Leupen, S. & Huang, P. L. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology 143, 2767-2774 (2002).
131. Huang, Z. et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265, 1883-1885 (1994).
132. Nathan, C. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest 100, 2417-2423 (1997).
133. Bogdan, C. Nitric oxide and the immune response. Nature Immunol. 2, 907-916 (2001).
134. Vallance, P. & Leiper, J. Blocking NO synthesis: how, where and why? Nature Rev. Drug Discov. 1, 939-950 (2002).
135. Mete, A. & Connolly, S. Inhibitors of the NOS enzymes: a patent review. IDrugs 6, 57-65 (2003).
136. Lirk, P., Hoffmann, G. & Rieder, J. Inducible nitric oxide synthase - time for reappraisal. Curr. Drug. Targets Inflamm. Allergy 1, 89-108 (2002).
137. McMillan, K. et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl Acad. Sci. USA 97, 1506-1511 (2000).
138. Ohtsuka, M. et al. PPA250 [3-(2,4-difluorophenyl)-6-[2-[4-(1H-imidazol-1-ylmethyl) phenoxy]ethoxy]-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic arthritis. J. Pharmacol. Exp. Ther. 303, 52-57 (2002).
139. Blasko, E. et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J. Biol. Chem. 277, 295-302 (2002).
140. Enkhbaatar, P. et al. Inducible nitric oxide synthase dimerization inhibitor prevents cardiovascular and renal morbidity in sheep with combined burn and smoke inhalation injury. Am. J. Physiol. Heart Circ. Physiol. 285, H2430-H2436 (2003).
141. Enkhbaatar, P. et al. The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. Am. J. Respir. Crit. Care Med. 167, 1021-1026 (2003).
142. Szalbolcs, M. J. et al. Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation 106, 2392-2396 (2002).
143. Chao, M. et al. Neurotrophin receptors: mediators of life and death. Brain Res. Brain Res. Rev. 26, 295-301 (1998).
144. Ibanez, C. F. et al. Disruption of the low affinity receptor-binding site in NGF allows neuronal survival and differentiation by binding to the trk gene product. Cell 69, 329-341 (1992).
145. Ryden, M. & Ibanez, C. F. A second determinant of binding to the p75 neurotrophin receptor revealed by alanine-scanning mutagenesis of a conserved loop in nerve growth factor. J. Biol. Chem. 272, 33085-33091 (1997).
146. Wiesmann, C., Ultsch, M. H., Bass, S. H. & de Vos, A. M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401, 184-188 (1999).
147. Niederhauser, O. et al. NGF ligand alters NGF signaling via p75(NTR) and trkA. J. Neurosci. Res. 61, 263-272 (2000).
148. Lee, A., Huang, L. & Ellman, J. A. General solid-phase method for the preparation of mechanism-based cysteine protease inhibitors. J. Am. Chem. Soc. 121, 9907-9914 (1999).
149. Otto, H.-H. & Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Rev. 97, 133-172 (1997).
150. Tsai, C. J., Lin, S. L., Wolfson, H. J. & Nussinov, R. Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Crit. Rev. Biochem. Mol. Biol. 1, 127-152 (1996).
151. Stites, W. E. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem. Rev. 97, 1233-1250 (1997).
152. Hu, Z., Ma, B., Wolfson, H. & Nussinov, R. Conservation of polar residues as hot spots at protein interfaces. Proteins 39, 331-342 (2000).
153. Atwell, S., Ultsch, M., De Vos, A. M. & Wells, J. A. Structural plasticity in a remodeled protein-protein interface. Science 278, 1125-1128 (1997).
154. Shulker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
155. Erlanson, D. A. et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97, 9367-9372 (2000).
156. Hann, M. M., Leach, A. R. & Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 855-864 (2001).
157. Oprea, T. I., Davis, A. M., Teague, S. J. & Leeson, R. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308-1315 (2001).
158. Lepre, C. A. et al. Applications of SHAPES screening in drug discovery. Comb. Chem. High. Throughput Screen. 5, 583-590 (2002).
159. Fejzo, J. et al. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 6, 755-769 (1999).
160. Hajduk, P. J., Meadows, R. P. & Fesik, S. W. NMR-based screening in drug discovery. Q. Rev. Biophys. 32, 211-240 (1999).
161. Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315-2317 (1999).
162. Hajduk, P. J. et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43, 4781-4786 (2000).
163. Nienaber, V. L. et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnol. 18, 1105-1108 (2000).
164. Carr, R. & Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discov. Today 7, 522-527 (2002).
165. Erlanson, D. A. et al. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering. J. Am. Chem. Soc. 125, 5602-5603 (2003).
166. Erlanson, D. A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nature Biotechnol. 21, 308-314 (2003).
167. Lebowitz, J., Lewis, M. S. & Schuck, P. Modern analytical ultracentrifugation in protein science: a tutorial review. Protein. Sci. 11, 2067-2079 (2002).
168. Philo, J. S. Sedimentation equilibrium analysis of mixed associations using numberical contraints to impose mass or signal conservation. Meth. Enzymol. 321, 100-120 (2000).
169. Arkin, M. & Lear, J. D. A new data analysis method to determine binding constants of small molecules to proteins using equilibrium analytical ultracentrifugation with absorption optics. Anal. Biochem. 299, 98-107 (2001).
170. Mayer, M. & Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123, 6108-6117 (2001).
171. Hajduk, P. J., Olejniczak, E. T. & Fesik, S. W. One-Dimensional relaxtion- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119, 12257-12261 (1997).
172. Campbell, A. P. & Sykes, B. D. The two-dimensional transferred nuclear Overhauser effect: theory and practice. Annu. Rev. Biophys. Biomol. Struct. 22, 99-122 (1993).
173. Day, Y. S. & Myszka, D. G. Characterizing a drug's primary binding site on albumin. J. Pharm. Sci. 92, 333-343 (2003).
174. Rich, R. L. & Myszka, D. G. Survey of the year 2000 commercial optical biosensor literature. J. Mol. Recognit. 14, 273-294 (2001).
175. Leavitt, S. & Freire, E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11, 560-566 (2001).
176. Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315-2317 (1999).
177. Blundell, T. L., Jhoti, H. & Abell, C. High-throughput crystallography for lead discovery in drug design. Nature Rev. Drug Discov. 1, 45-54 (2002).